Tirzepatide Tracker: What to Track on Mounjaro & Zepbound

01

Tirzepatide, Mounjaro, Zepbound: brand vs. molecule

This trips people up constantly, so get it straight before you track anything. Tirzepatide is the molecule (the generic drug). Mounjaro and Zepbound are brand names for that same molecule, made by Eli Lilly, approved for different uses.

That Mounjaro/Zepbound split is the US picture.

In the EU, Brazil, China and a number of other countries there is no Zepbound brand: Mounjaro itself is approved for both type 2 diabetes and weight management (EU product information; Brazil's ANVISA, June 2025; China's NMPA, July 2024).

Because the active ingredient is identical, the tracking data is essentially the same for both — dose (mg), injection site, weight, protein, side effects.

Your indication changes what your prescriber is watching (blood glucose vs. weight and waist), but the log itself barely changes.

That is exactly why an ingredient-level tracker works: pick your brand page for the extras (Mounjaro tracker / Zepbound tracker) and use this page for the shared core.

A note on compounded tirzepatide. During the 2022–2024 shortage, compounding pharmacies sold non-brand "compounded tirzepatide." The FDA declared the shortage resolved in October 2024 and ended enforcement discretion for compounders in early 2025 (503A pharmacies on February 18, 2025; 503B outsourcing facilities on March 19, 2025), so large-scale compounding is no longer permitted outside narrow exceptions (FDA).

Compounded versions are not FDA-approved, and their concentration and dosing can differ from the pens — so if you were ever given one, log the exact strength and volume you injected, not a brand mg number.

02

Why tracking matters on tirzepatide specifically

Three things about tirzepatide make tracking more than a nice-to-have:

03

What to track on tirzepatide (and why each one matters)

Here is the core tirzepatide dataset. Use it as your checklist whether you track on paper, in a spreadsheet, or in an app — it is the same for Mounjaro and Zepbound.

Dose date and your tirzepatide titration schedule

Tirzepatide is deliberately started low and increased in 2.5 mg steps, no sooner than every four weeks, to reduce gastrointestinal side effects.

Per the FDA label and Eli Lilly's dosing guidance, the escalation is 2.5 mg (weeks 1–4, a starting dose only — not a maintenance dose) → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg maximum, each step held for at least four weeks before the next increase (FDA Zepbound prescribing information; Zepbound dosing).

The approved maintenance doses are 5, 10, or 15 mg — many people stay at 5 or 10 mg if that dose is working and well tolerated.

Because the dose changes on a calendar, logging which mg you took on which date is the single most useful thing you can record, and it makes each dose-adjustment conversation faster.

The missed-dose rule (worth getting right). Tirzepatide uses a 4-day (96-hour) rule — shorter than semaglutide's 5-day window (Ozempic "within 5 days"; Wegovy's US "next dose more than 2 days away" wording describes the same window), a common point of confusion when people switch.

Per Eli Lilly: if you miss a dose, take it as soon as possible within 4 days (96 hours); if more than 4 days have passed, skip the missed dose and resume on your regular day. Never take two doses within 3 days of each other (Mounjaro medication guide; how to use Mounjaro).

A tracker that timestamps every shot turns this into a glance.

Injection site and rotation

Tirzepatide is injected subcutaneously into one of three areas: the abdomen (keep at least two inches from the navel), the front of the thigh, or the back of the upper arm (usually with help), rotating each week (how to use Mounjaro).

Repeatedly injecting the same exact spot can cause lipohypertrophy — lumpy scar tissue that changes how the medicine is absorbed.

The problem is memory: after a few weeks, nobody recalls "left thigh or right arm last time?" This is where a tracker earns its keep — a good one shows a body map with your recent sites highlighted so you always pick a fresh one.

Weight, glucose, measurements, and photos

On Zepbound, weight is the headline number for a tirzepatide weight loss tracker — but it is noisy day to day.

Weigh in at the same time (typically morning, after the bathroom, before eating) and let the trend line, not a single reading, tell the story. Plateaus are common and medically explainable.

On Mounjaro, blood glucose is the primary number your clinician watches; log it as directed.

For both, waist measurements and progress photos every 2–4 weeks capture body-composition change the scale hides — which matters most exactly when the number stalls.

Protein, food, and protecting muscle

This is the most under-appreciated part of a tirzepatide journey.

Because tirzepatide sharply reduces appetite — in the SURMOUNT-1 trial the 15 mg dose produced an average 20.9% body-weight loss over 72 weeks (NEJM, 2022) — a meaningful share of the weight you lose can be lean body mass (note that some of this is water and organ tissue, not only skeletal muscle) (review in Frontiers / PMC).

Muscle protects your metabolism and long-term results. Two trackable habits do the heavy lifting:

1. Protein. Aim for a high-protein target at each meal (many clinicians suggest distributing protein across the day). When appetite drops, protein is usually the first thing to fall — so logging it keeps it front of mind.
2. Resistance training. Strength work is the strongest defense against muscle loss on a GLP-1; log your sessions like you log your dose.

Side effects — normal vs. red flag

The most common tirzepatide side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite.

These usually appear or worsen right after a dose increase and settle as your body adapts.

Rare but serious risks include pancreatitis and gallbladder disease, which need prompt medical assessment.

Logging what you felt, how severe, and how many days since your last dose or dose step-up turns a vague "I've felt off" into a clear pattern.

For the full symptom-by-symptom breakdown, see our guide to GLP-1 side effects.

If you use birth-control pills: the US tirzepatide labels (Mounjaro, Zepbound) advise switching to a non-oral method or adding a barrier method for 4 weeks after starting and for 4 weeks after each dose increase.

The EU label does not require this, so ask your prescriber which applies to you.

Safety basics for any GLP-1 log. Don't use these medicines if you or a close relative has had medullary thyroid cancer, or if you have MEN 2.

They are not used during pregnancy — tell your prescriber right away if you become pregnant or plan to, because some must be stopped weeks to months beforehand.

If you also take insulin or a sulfonylurea, watch for low blood sugar (shakiness, sweating, confusion).

Vomiting or diarrhea that keeps you from holding down fluids can dehydrate you and strain your kidneys — call your clinician.

A tracker organizes your records; the package leaflet in your country and your prescriber come first.

04

How tirzepatide differs from semaglutide (and why your log changes)

If you switched from Ozempic, Wegovy, or Rybelsus, do not copy your old habits blindly.

Tirzepatide is a dual GIP/GLP-1 agonist, while semaglutide acts on GLP-1 alone — and the practical tracking rules differ:

The two big log changes: your mg ladder is different, and your missed-dose window is different. Get both right in your tracker so a brand switch does not create a dosing error.

For the full comparison, see semaglutide vs. tirzepatide.

05

How to build a tirzepatide tracking routine in 6 steps

You do not need a complicated system — you need a repeatable one. This takes under two minutes a week for the core log, plus quick daily taps.

1. 1

   Set a weekly injection reminder.

   Pick a consistent day and time and set a recurring alert so a late shot never sneaks up on you.

2. 2

   Log the dose and site right after injecting.

   Record the mg amount and mark the body-map zone, so next week's rotation is obvious.

3. 3

   Weigh in (or check glucose) on fixed days.

   Choose 1–3 mornings a week for weight, same conditions; log glucose as your clinician directs.

4. 4

   Track protein and water daily.

   A quick tap per meal is enough to keep muscle protection on track.

5. 5

   Note side effects when they happen.

   Record the symptom, severity, and days since your last dose or dose increase.

6. 6

   Photo every 2–4 weeks and review before each visit.

   Same lighting, same angle — and bring your dose log and side-effect timeline to your clinician.

06

Do you need a tirzepatide app, or is a notebook fine?

Honestly, any tracking beats none — a tirzepatide diary in a notebook works.

What an app adds is the automation of the parts people forget: the weekly reminder, the injection-site rotation map, the trend line that smooths daily weight noise, and a side-effect timeline you can hand to your clinician.

Neither Mounjaro nor Zepbound ships with a dedicated companion app, so most people use a general GLP-1 or wellness tracker.

If you want your dose log living next to the daily habits that protect your results — protein, movement, hydration, weight and body-composition trends — a wellness app like HAVIT is a natural home for it.

Compare a few options in our best GLP-1 tracker apps guide and pick what you will actually keep using; consistency matters far more than the brand.

07

Related guides

• Mounjaro tracker: what to log on Mounjaro and how
• Zepbound tracker: what to log on Zepbound and how
• Semaglutide vs. tirzepatide: which GLP-1 is right for you?
• The complete GLP-1 tracker app guide

08

Why HAVIT — Medication + Behavior Change, in One App

GLP-1 medications can meaningfully reduce weight — but the number on the scale is only part of the story.

In trials of GLP-1-based therapies, lean mass (which includes muscle but also organs, bone, and water) has made up anywhere from about 15% or less to 40–60% of the weight lost (Neeland et al., Diabetes, Obesity and Metabolism, 2024), and results tend to fade once the medication stops unless new habits take their place.

That's why leading guidance treats medication as one part of care, not the whole: the U.S. Preventive Services Task Force recommends that adults with obesity be offered intensive, multicomponent behavioral interventions (USPSTF, Grade B).

HAVIT is built for exactly this moment — one app that unites medication tracking, body composition, nutrition and protein, daily habit-building, and an AI coach that adapts to you.

Across our own 1,090 GLP-1 users, the most consistent trackers built the strongest habits (see the GLP-1 habit report).

Manage the medicine and the muscle — together. Start with HAVIT →

Related articles